[go: up one dir, main page]

JO3541B1 - علاجات طبية قائمة على اناموريلين - Google Patents

علاجات طبية قائمة على اناموريلين

Info

Publication number
JO3541B1
JO3541B1 JOP/2015/0210A JOP20150210A JO3541B1 JO 3541 B1 JO3541 B1 JO 3541B1 JO P20150210 A JOP20150210 A JO P20150210A JO 3541 B1 JO3541 B1 JO 3541B1
Authority
JO
Jordan
Prior art keywords
anamorelin
medical treatments
treatments based
medical
methods
Prior art date
Application number
JOP/2015/0210A
Other languages
English (en)
Inventor
Allen Suzan
Lu Ming
Friend John
Duus Elizabeth
Polvino William
Mann William
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3541(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Application granted granted Critical
Publication of JO3541B1 publication Critical patent/JO3541B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

تم وصف طرق لعلاج حالات تتعلق بالسرطان باستخدام اناموريلين.
JOP/2015/0210A 2014-09-04 2015-08-30 علاجات طبية قائمة على اناموريلين JO3541B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04

Publications (1)

Publication Number Publication Date
JO3541B1 true JO3541B1 (ar) 2020-07-05

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0210A JO3541B1 (ar) 2014-09-04 2015-08-30 علاجات طبية قائمة على اناموريلين

Country Status (44)

Country Link
US (5) US9675600B2 (ar)
EP (2) EP3590338A3 (ar)
JP (3) JP6356907B2 (ar)
KR (3) KR102307275B1 (ar)
CN (5) CN113577074A (ar)
AP (1) AP2017009772A0 (ar)
AR (1) AR103118A1 (ar)
AU (1) AU2015312231B2 (ar)
BR (1) BR112017003552A2 (ar)
CA (1) CA2959158A1 (ar)
CL (1) CL2017000494A1 (ar)
CO (1) CO2017003263A2 (ar)
CR (1) CR20170121A (ar)
CY (1) CY1122746T1 (ar)
DK (1) DK3188599T3 (ar)
DO (1) DOP2017000055A (ar)
EA (1) EA035578B1 (ar)
EC (1) ECSP17019893A (ar)
ES (1) ES2761777T3 (ar)
GE (1) GEP20186939B (ar)
HR (1) HRP20192345T1 (ar)
HU (1) HUE046894T2 (ar)
IL (1) IL250692B (ar)
JO (1) JO3541B1 (ar)
LT (1) LT3188599T (ar)
MA (1) MA40607B1 (ar)
MD (1) MD4710C1 (ar)
ME (1) ME03597B (ar)
MX (1) MX361741B (ar)
MY (1) MY187167A (ar)
NI (1) NI201700024A (ar)
PE (1) PE20171109A1 (ar)
PH (1) PH12017500392B1 (ar)
PL (1) PL3188599T3 (ar)
PT (1) PT3188599T (ar)
RS (1) RS59751B1 (ar)
SG (1) SG11201701567UA (ar)
SI (1) SI3188599T1 (ar)
SV (1) SV2017005400A (ar)
TN (1) TN2017000040A1 (ar)
TW (1) TWI639429B (ar)
UA (1) UA120765C2 (ar)
UY (1) UY36286A (ar)
WO (1) WO2016036598A1 (ar)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
CN113577074A (zh) 2014-09-04 2021-11-02 赫尔森保健股份公司 基于阿拉莫林的药物治疗
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
AU2019401214B2 (en) 2018-12-20 2025-09-04 Société des Produits Nestlé S.A. Peanut oral immunotherapy dosing schedule for missed doses
US11229673B2 (en) 2019-05-10 2022-01-25 Société des Produits Nestlé S.A. Methods for improving the quality of life of a patient with a peanut allergy
KR20220054244A (ko) 2019-08-30 2022-05-02 헬신 헬스케어 에스아 개선된 안정성을 갖는 아나모렐린 정제의 제조 방법
US20240139176A1 (en) * 2019-10-24 2024-05-02 Toray Industries, Inc. Methods of treating or preventing cachexia
JP2024534464A (ja) * 2021-09-17 2024-09-20 小野薬品工業株式会社 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法
WO2025004650A1 (ja) * 2023-06-28 2025-01-02 日清オイリオグループ株式会社 中高年者の疲労感を軽減するための剤及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
WO2005014032A2 (en) * 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
KR20070010151A (ko) 2004-03-30 2007-01-22 사파이어 세라퓨틱스, 인크. 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법
EP2298760B1 (en) * 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
KR20090112720A (ko) * 2007-02-13 2009-10-28 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법
TWI429436B (zh) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
US20150099709A1 (en) * 2012-05-25 2015-04-09 Raqualia Pharma Inc. Ghrelin receptor agonists for the treatment of achlorhydria
CN113577074A (zh) 2014-09-04 2021-11-02 赫尔森保健股份公司 基于阿拉莫林的药物治疗

Also Published As

Publication number Publication date
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
MD4710B1 (ro) 2020-09-30
WO2016036598A1 (en) 2016-03-10
LT3188599T (lt) 2019-12-10
MD4710C1 (ro) 2021-04-30
KR20180085047A (ko) 2018-07-25
PL3188599T3 (pl) 2020-06-01
CN107205389A (zh) 2017-09-26
AR103118A1 (es) 2017-04-19
KR102234319B1 (ko) 2021-04-01
CR20170121A (es) 2017-07-17
TW201613587A (en) 2016-04-16
MX361741B (es) 2018-12-14
CY1122746T1 (el) 2021-03-12
TWI639429B (zh) 2018-11-01
MX2017002825A (es) 2017-09-28
UA120765C2 (uk) 2020-02-10
DOP2017000055A (es) 2017-08-15
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
US10894041B2 (en) 2021-01-19
EP3188599A4 (en) 2017-10-11
US9675600B2 (en) 2017-06-13
JP2018154655A (ja) 2018-10-04
JP2017526695A (ja) 2017-09-14
EP3590338A2 (en) 2020-01-08
US20190175574A1 (en) 2019-06-13
CN109172575A (zh) 2019-01-11
NI201700024A (es) 2017-07-18
ME03597B (me) 2020-07-20
JP2021080281A (ja) 2021-05-27
BR112017003552A2 (pt) 2017-12-05
PH12017500392B1 (en) 2018-08-31
EP3188599B1 (en) 2019-10-02
KR102307275B1 (ko) 2021-09-30
SG11201701567UA (en) 2017-03-30
JP6923486B2 (ja) 2021-08-18
ES2761777T3 (es) 2020-05-21
CA2959158A1 (en) 2016-03-10
MY187167A (en) 2021-09-07
CO2017003263A2 (es) 2017-07-28
NZ729673A (en) 2023-09-29
EP3590338A3 (en) 2020-03-18
CN113577074A (zh) 2021-11-02
US20240024303A1 (en) 2024-01-25
US20170296526A1 (en) 2017-10-19
KR20170047372A (ko) 2017-05-04
SI3188599T1 (sl) 2020-02-28
US11723902B2 (en) 2023-08-15
HRP20192345T1 (hr) 2020-03-20
PH12017500392A1 (en) 2017-07-17
UY36286A (es) 2016-02-29
AP2017009772A0 (en) 2017-02-28
RS59751B1 (sr) 2020-02-28
KR101881264B1 (ko) 2018-07-23
SV2017005400A (es) 2017-04-20
AU2015312231B2 (en) 2017-10-19
AU2015312231A1 (en) 2017-03-23
CL2017000494A1 (es) 2017-09-15
JP6356907B2 (ja) 2018-07-11
JP7044918B2 (ja) 2022-03-30
CN113577073A (zh) 2021-11-02
PE20171109A1 (es) 2017-08-07
PT3188599T (pt) 2020-01-15
US20210093627A1 (en) 2021-04-01
MA40607B1 (fr) 2019-11-29
IL250692B (en) 2019-05-30
IL250692A0 (en) 2017-04-30
KR20210035923A (ko) 2021-04-01
US10278964B2 (en) 2019-05-07
ECSP17019893A (es) 2017-05-31
TN2017000040A1 (en) 2018-07-04
US20160067236A1 (en) 2016-03-10
EP3188599A1 (en) 2017-07-12
CN107375285A (zh) 2017-11-24
HUE046894T2 (hu) 2020-04-28
MD20170025A2 (ro) 2017-07-31

Similar Documents

Publication Publication Date Title
IL249065A0 (en) Combination therapies for the treatment of cancer
NZ731467A (en) Anti-tim3 antibodies and methods of use
EP3630089A4 (en) PROCEDURE FOR CANCER THERAPY
EP3393475A4 (en) METHODS OF TREATING CANCER
EP3180010A4 (en) Combination therapy for treating cancer
LT3283527T (lt) Kompleksinė terapija vėžio gydymui
PH12016501978A1 (en) Treatment of nafld and nash
PL3851537T3 (pl) Leczenie hiperbilirubinemii
EP3233089A4 (en) Method of treating cancer with cgamp or cgasmp
PL3580211T3 (pl) 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
IL258521B1 (en) Combination therapy for the treatment of cancer
EP3110443A4 (en) Combination method for treatment of cancer
EP3134436A4 (en) Treatment of h-ras-driven tumors
EP3193884A4 (en) Combination therapy for treating cancer
EP3193905A4 (en) Methods of treating cervical cancer
MX2017007707A (es) Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.
EP3226901A4 (en) Combination therapy for treatment of cancer
EP3185884A4 (en) Combination therapy for treatment of cancer
EP3119390A4 (en) Methods of treating cancer
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
ZA201703467B (en) Methods of treating ocular conditions
GB201408297D0 (en) Treatment of cancer
EP3389670A4 (en) METHODS OF TREATING BREAST CANCER